Gabriela Morales-Rivera > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices
100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Gabriela Morales-Rivera
Position
Partner
Career
Gabriela (Gaby) Morales-Rivera is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals, and medical devices. Gaby represents public and private companies in startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, strategic investments, and other complex transactions.
She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Gaby has worked with many of her company-side clients since their initial founding and funding.
Education
JD, 2015
Boston University School of Law
BA, 2012
Swarthmore College (with high honors)
Lawyer Rankings
United States > Finance > Capital markets: equity offerings
Overseeing high-profile public offerings for an underwriting syndicate and advising issuers on both debt and equity follow-on offerings, Goodwin draws upon strong multi-jurisdictional capabilities and substantial bench-strength. The practice mainly represents private companies in complex financings and IPOs, alongside supporting public corporations in their SEC reporting and corporate governance proceedings. Edwin O’Connor heads the New York offering, being a specialist in the tech and life sciences sectors, while Silicon Valley-based Bradley Weber is highly knowledgeable in IPOs and PIPEs. From Boston, Joseph Theis is an expert in securities law and SEC compliance measures, Robert Puopolo stands out for his M&A and joint venture work, and both Marishka DeToy and Gabriela Morales-Rivera are also cited as key for their coverage of SEC compliance and venture capital financing matters.
Lawyer Rankings
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation